Gastric cancer patients undergoing chemotherapy
Conditions
Interventions
Treatment group:Oral nutritional supplements containing high levels of DHA
Control group:Oral nutritional supplementation (nutrison )
Sponsors
Shandong Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with gastric cancer through histological or cytological diagnosis and those planning to receive chemotherapy. 2. Karnofsky (KPS) score >= 60 points. 3. The subjects or their guardians (or authorized persons) fully understand the research process of this project, agree to participate, and sign a written informed consent form. 4. Age above 18 years old and below 80 years old, gender not limited.
Exclusion criteria
Exclusion criteria: 1. Individuals allergic to experimental drugs, whey protein, fish oil, and algal oil; 2. Consuming muscle growth support substances (such as synthetic metabolic enzymes) and additional fish oil or DHA substitutes in the past 4 weeks; 3. There are contraindications for oral/enteral nutrition (such as active gastrointestinal bleeding, intestinal ischemia, etc.); 4. Those who receive treatment through radiation, endocrine, immunological and other methods, or receive end-of-life palliative care; 5. Cognitive impairment or severe disability, inability to understand research and sign informed consent forms; 6. Breastfeeding or pregnancy; 7. Contraindications for the measurement of in body composition in patients with implanted pacemakers, cochlear implants, etc; 8. Patients receiving parenteral nutrition; 9. Patients taking drugs that affect metabolism (such as synthetic metabolic steroids, appetite suppressants, etc.); 10. Merge malignant tumors from other parts. 11. Combined renal dysfunction (glomerular filtration rate<30mL/min/1.73m^2); Severe heart failure (New York Heart Association functional class IV); Chronic diseases such as liver insufficiency (bilirubin is 5 times higher than the upper limit of normal value), diabetes, etc. Type 2 diabetes is diagnosed according to the Chinese diabetes prevention and treatment guide (2020 version), and type 1 diabetes is diagnosed according to the Chinese diabetes diagnosis and treatment guide (2021 version). 12. Expected survival period <= 180 days; 13. Currently participating in other clinical trials; 14.Other situations that are not suitable for participating in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| weight; | — |
Secondary
| Measure | Time frame |
|---|---|
| nutritional status;C-reactive protein;Adverse event;serum albumin;Other indicators of body measurement;Immune related indicators;Serum prealbumin;Inflammatory related indicators;Evaluation of quality of life;Serum total protein;Hospitalization expenses;appetite related indicators; | — |
Countries
China
Contacts
Public ContactLi Feng
Shandong Provincial Hospital
Outcome results
None listed